STOCK TITAN
  1. Home
  2. News
  3. JAZZ

Jazz Pharmaceuticals plc - JAZZ STOCK NEWS

Welcome to our dedicated news page for Jazz Pharmaceuticals plc (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jazz Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jazz Pharmaceuticals plc's position in the market.

News
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will report its 2024 first quarter financial results on May 1, 2024, after the close of the U.S. financial markets. The company will host a live audio webcast to discuss the results and provide a business and financial update. Interested parties can access the webcast through the Investors section of the Jazz Pharmaceuticals website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) presented 13 abstracts at the 76th Annual American Academy of Neurology Meeting, showcasing real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex in treatment-resistant epilepsies. The company highlighted its diverse neuroscience portfolio and commitment to advancing treatments for serious sleep disorders, rare epilepsy syndromes, and movement disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
News
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
Rhea-AI Summary
Jazz Pharmaceuticals plc submits BLA for zanidatamab in HER2-positive biliary tract cancer, achieving positive results in Phase 2b trial and opening Phase 3 trial for enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
News
Cancer and the Combination Approach
Rhea-AI Summary
Jazz Pharmaceuticals, led by Liz Henderson, focuses on innovating oncology drug manufacturing to address supply chain issues in the pharmaceutical industry. The company emphasizes the importance of reliable drug supply for effective treatments in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
-
News
Jazz Pharmaceuticals Celebrates International Women’s Day
Rhea-AI Summary
Jazz Pharmaceuticals celebrates International Women's Day by hosting a fireside chat with Cheekbone Beauty Cosmetics CEO to promote women in the biotechnology industry. They highlight their commitment to diversity, equity, and inclusion through various initiatives and appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
News
Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month
Rhea-AI Summary
Jazz Pharmaceuticals' JazzSoul forum celebrated U.S. Black History Month by honoring the contributions of the African diaspora. The event featured C.B. Bucknor, a Black MLB Umpire, and Dr. B. Hutchinson, a sleep specialist, cardiologist, and chair of the Association of Black Cardiologists, who discussed disparities in sleep health and cardiovascular risk factors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
News
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
Rhea-AI Summary
Jazz Pharmaceuticals plc will host a virtual R&D Day focused on zanidatamab, a bispecific antibody in late-stage development for HER2-positive cancers. The event will showcase clinical data and treatment potential for biliary tract, gastroesophageal adenocarcinoma, and breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences
-
News
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
Rhea-AI Summary
Jazz Pharmaceuticals plc (JAZZ) reported total revenues of $3.8 billion in 2023 with a 27% year-over-year increase driven by key growth drivers like Xywav, Epidiolex, and Rylaze. The company achieved its first $1 billion revenue quarter and anticipates double-digit revenue growth in 2024. Multiple late-stage pipeline catalysts are expected, with a 2024 revenue guidance of $4.0 to $4.2 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
earnings
-
News
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
Rhea-AI Summary
Jazz Pharmaceuticals plc appoints Patrick Kennedy, an experienced leader, to its Board of Directors, enhancing the company's focus on creating value for shareholders. Kennedy's financial and operating expertise aligns with Jazz's growth-oriented approach, aiming to transform patients' lives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
management
News
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Rhea-AI Summary
Jazz Pharmaceuticals appoints Philip Johnson as Executive Vice President and CFO, bringing over 35 years of financial experience to the leadership team. Johnson will oversee various financial functions and drive growth and diversification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
management
Stock JAZZ logo
Jazz Pharmaceuticals plc

Nasdaq:JAZZ

JAZZ Rankings

#994 Ranked by Market Cap
#2855 Ranked by Stock Gains
N/A Ranked by Dividends

JAZZ Stock Data

6.89B
60.45M
2.82%
95.89%
5.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About JAZZ

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni